Published: 03/28/2022 12:50 GMT CorMedix Inc (CRMD) - Cormedix Inc. Announces FDA Acceptance of Resubmission of New Drug Application for Defencath.
Cormedix Inc - FDA Considers Resubmission As a Complete, Class 2 Response With a Six Month Review Cycle.
